Key result
Elevated plasma GMP-140 is linked to acute myocardial infarction, cardiopulmonary bypass, and stroke.
Why the study?
Platelet activation and endothelium damage are assumed to play a critical role in thrombotic disorders, but plasma GMP-140 detection in these conditions was not established.
Can plasma GMP-140 be detected and does it increase in patients with thrombotic disorders (AMI, cerebral thrombosis) or during CPB?
Observational
Can plasma GMP-140 be detected and does it increase in patients with thrombotic disorders (AMI, cerebral thrombosis) or during CPB?
Effect estimate: r = -0.81
p-value: p=<0.01
Plasma GMP-140 can be sensitively detected using a novel radioimmunoassay and is significantly elevated in acute thrombotic conditions like AMI, cerebral thrombosis, and during CPB, reflecting platelet activation.
No takes yet. Share an insight, caveat, or question.
GMP-140 elevation may mark platelet activation in bypass and acute thrombosis; leaves open diagnostic utility pending prospective validation.
Wu et al. (2009) conducted an observational in Thrombotic diseases. Thrombotic diseases and cardiopulmonary bypass vs. Normal subjects was evaluated on Plasma GMP-140 concentration (r = -0.81, p=<0.01). Plasma GMP-140 concentration was 10.0 ng/ml in normal subjects and increased significantly during cardiopulmonary bypass, acute myocardial infarction, and acute cerebral thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: